Annovis Bio Inc (ANVS)vsModerna Inc (MRNA)
ANVS
Annovis Bio Inc
$1.04
-7.14%
HEALTHCARE · Cap: $47.72M
MRNA
Moderna Inc
$145.62
+1.29%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
ANVS leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
ANVS
Avoid17
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ANVS.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$145.62
$10.65 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ANVS
ANVS has a balanced fundamental profile.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ANVS
The primary concerns for ANVS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ANVS profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
ANVS carries more volatility with a beta of 1.24 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
ANVS generates stronger free cash flow (-22M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 17/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Annovis Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?